In HNF1A-MODY, weekly GLP-1 RA monotherapy has maintained excellent glycaemic control without hypoglycaemia, offering a clear alternative when sulfonylureas lead to weight gain or recurrent hypoglycaemic episodes [11]. This evidence concerns the gene HNF1A and MODY.